Home・Akciju saraksts・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Slēgts

SektorsVeselības aprūpe

28.36 6.06

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

25.98

Max

27.02

Galvenie mērījumi
By Trading Economics
Ienākumi	-29M -11M
Pārdošana	-24M 105M
EPS	-0.09
Peļņas marža	-10.717
Darbinieki	354
EBITDA	-28M -6.3M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+33.92% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 5. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	307M 3.2B
Iepriekšējā atvēršanas cena	22.3
Iepriekšējā slēgšanas cena	28.36

Ziņu noskaņojums

By Acuity

50%

175 / 340 Rangs Healthcare

Arcutis Biotherapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. aug. 19:46 UTC

Arcutis Biotherapeutics is advancing during Tuesday's session amid a broader market boost from declining crude oil prices, easing inflation concerns.

2026. g. 3. aug. 21:01 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading, continuing a decline despite broader market gains and optimism over lower oil prices.

2026. g. 31. jūl. 20:03 UTC

Arcutis Biotherapeutics Inc shares are lower today, continuing a decline since Thursday's close amid broader weak performance and no specific news identified.

2026. g. 30. jūl. 23:51 UTC

Arcutis Biotherapeutics shares are lower in after-market trading, reflecting a broader decline since Thursday's close amid mixed Asian equity performance and geopolitical concerns.

2026. g. 29. jūl. 19:19 UTC

Arcutis Biotherapeutics Inc. shares are lower as market sentiment reflects concerns over the Federal Reserve's upcoming monetary policy announcement amid inflationary pressures.

2026. g. 28. jūl. 18:06 UTC

Arcutis Biotherapeutics Inc. shares are higher today, supported by a broader rally in biotechnology stocks, despite no specific company news identified.

2026. g. 27. jūl. 16:07 UTC

Social Media

Arcutis Biotherapeutics gained today after an Overweight rating from MS, which highlighted strong sales expectations for ZORYVE and cash flow break-even prospects.

2026. g. 24. jūl. 19:16 UTC

Arcutis Biotherapeutics Inc. shares are lower today, reflecting routine performance within a narrow range amid no specific company news identified.

2026. g. 21. jūl. 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher, supported by positive market sentiment from strong earnings reports. Shares remain above their 20-day moving average.

2026. g. 20. jūl. 20:14 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading. No specific company news was identified to explain this movement.

Salīdzinājums

Cenas izmaiņa

Arcutis Biotherapeutics Inc Prognoze

Cenas mērķis

By TipRanks

33.92% augšup

Prognoze 12 mēnešiem

Vidējais 34.86 USD 33.92%

Augstākais 36 USD

Zemākais 34 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Arcutis Biotherapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Arcutis Biotherapeutics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

175 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.